免疫检查点抑制剂治疗口腔鳞癌的研究进展

doi:10.11904/j.issn.1002-3070.2022.01.015

Abstract

Abstract: Oral squamous cell carcinoma(OSCC)is a common type of oral head and neck tumors.The significant pathological features are immunosuppression and lymphocyte infiltration.Tumor cells often evade immune surveillance by activating different immune checkpoints,thereby avoiding the body's anti-tumor immune response.The current treatment methods have certain limitations,and the side effects are relatively large.Therefore,it is particularly important to research and develop new treatment methods and routes of administration.The introduction of immune checkpoint inhibitors(ICIs)has led to a shift in the clinical treatment model of OSCC.This article discusses the advantages of the anti-programmed cell death protein 1(PD-1)in the treatment of OSCC,and reviews the current developments in biomarkers that can be used to predict efficacy.

Key words: Squamous cell carcinoma, Immunotherapy, Biomarker, Programmed cell death receptor

CLC Number:

R739.81

WANG Siran, HU Weiping. Research progress of immune checkpoint inhibitors in the treatment of oral squamous cell carcinoma[J]. Journal of Practical Oncology, 2022, 36(1): 79-83.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.01.015

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I1/79

References

1 de Vicente JC,Rodríguez-Santamarta T,Rodrigo JP,et al.PD-L1 expression in tumor cells is an independent unfavorable prognostic factor in oral squamous cell carcinoma[J].Cancer Epidemiol Biomarkers Prev,2019,28(3):546-554.
2 Shaw R,Beasley N.Aetiology and risk factors for head and neck cancer:United Kingdom national multidisciplinary guidelines[J].J Laryngol Otol,2016,130(2):9-12.
3 Kaidar-Person O,Gil Z,Billan S.Precision medicine in head and neck cancer[J].Drug Resist Updat,2018,40:13-16.
4 Goertzen C,Mahdi H,Laliberte C,et al.Oral inflammation promotes oral squamous cell carcinoma invasion[J].Oncotarget,2018,9(49):29047-29063.
5 Pai-Scherf L,Blumenthal GM,Li H,et al.FDA approval summary:pembrolizumab for treatment of metastatic non-small cell lung cancer:first-line therapy and beyond[J].Oncologist,2017,22(11):1392-1399.
6 Takahashi H,Sakakura K,Arisaka Y,et al.Clinical and biological significance of PD-L1 expression within the tumor microenvironment of oral squamous cell carcinoma[J].Anticancer Res,2019,39(6):3039-3046.
7 Ishida Y,Agata Y,Shibahara K,et al.Induced expression of PD-1,a novel member of the immunoglobulin gene superfamily,upon programmed cell death[J].EMBO J,1992,11(11):3887-3895.
8 Kim JW,Lee J,Hong SM,et al.Circulating CCR7^loPD-1^hi follicular helper T cells indicate disease activity and glandular inflammation in patients with primary Sjögren's Syndrome[J].Immune Netw,2019,19(4):e26.
9 Fonseca VR,Romão VC,Agua-Doce A,et al.The ratio of blood T follicular regulatory cells to T follicular helper cells marks ectopic lymphoid structure formation while activated follicular helper T cells indicate disease activity in primary Sjögren's Syndrome[J].Arthritis Rheumatol,2018,70(5):774-784.
10 Hirai M,Kitahara H,Kobayashi Y,et al.Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment[J].Int J Oncol,2017,50(1):41-48.
11 Meehan K,Leslie C,Lucas M,et al.Characterization of the immune profile of oral tongue squamous cell carcinomas with advancing disease[J].Cancer Med,2020,9(13):4791-4807.
12 Ribas A.Tumor immunotherapy directed at PD-1[J].N Engl J Med,2012,366(26):2517-2519.
13 Sun C,Mezzadra R,Schumacher TN.Regulation and function of the PD-L1 checkpoint[J].Immunity,2018,48(3):434-452.
14 Sznol M,Chen L.Antagonist antibodies to PD-1 and B7-H1(PD-L1)in the treatment of advanced human cancer[J].Clin Cancer Res,2013,19(5):1021-1034.
15 Mann JE,Hoesli R,Michmerhuizen NL,et al.Surveilling the potential for precision medicine-driven PD-1/PD-L1-targeted therapy in HNSCC[J].J Cancer,2017,8(3):332-344.
16 Sullivan RJ,Flaherty KT.Pembrolizumab for treatment of patients with advanced or unresectable melanoma[J].Clin Cancer Res,2015,21(13):2892-2897.
17 Ferris RL,Blumenschein G Jr,Fayette J,et al.Nivolumab for recurrent squamous-cell carcinoma of the head and neck[J].N Engl J Med,2016,375(19):1856-1867.
18 Nivolumab doubles survival for patients with HNSCC[J].Cancer Discov,2016,6(7):3.
19 Rose S.Pembrolizumab has antitumor activity in advanced head and neck cancer[J].Cancer Discovery,2016,6(7):693.
20 Cohen EEW,Soulières D,Le Tourneau C,et al.Pembrolizumab versus methotrexate,docetaxel,or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma(KEYNOTE-040):a randomised,open-label,phase 3 study[J].Lancet,2019,393(10167):156-167.
21 Foy JP,Bertolus C,Michallet MC,et al.The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade[J].Ann Oncol,2017,28(8):1934-1941.
22 Cai Y,Wang F,Liu Q,et al.A novel humanized anti-PD-1 monoclonal antibody potentiates therapy in oral squamous cell carcinoma[J].Invest New Drugs,2019,37(5):799-809.
23 张连齐,李吉辰,朴松林,等.PD-L1与MTA1在口腔鳞癌中的表达与临床意义[J].实用肿瘤学杂志,2020,34(3):220-224.
24 Zandberg DP,Algazi AP,Jimeno A,et al.Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma:results from a single-arm,phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy[J].Eur J Cancer,2019,107:142-152.
25 Zandberg D,Algazi A,Jimeno A,et al.1042Odurvalumab for recurrent/metastatic(r/m)head and neck squamous cell carcinoma(HNSCC):preliminary results from a single-arm,phase 2 study[J].Ann Oncol,2017,28(suppl 5):1-7.
26 Bahleda R,Braiteh FS,Balmanoukian AS,et al.Logn-term safety and clinical outcomes of atezolizumab in head and neck cancer:phase ia trial results[J].Ann Oncol,2017,28(Suppl 5):372-394.
27 Colevas AD,Bahleda R,Braiteh F,et al.Safety and clinical activity of atezolizumab in head and neck cancer:results from a phase I trial[J].Ann Oncol,2018,29(11):2247-2253.
28 Tang X,Chen S,Sui Q,et al.Response to nivolumab combining radiotherapy and nimotuzumab in metastatic oral squamous cell carcinoma patient with strong PD-L1 expression:a case report[J].Ann Transl Med,2020,8(6):402.
29 Siu LL,Even C,Mesía R,et al.Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low/negative recurrent or metastatic HNSCC:The phase 2 CONDOR randomized clinical trial[J].JAMA Oncol,2019,5(2):195-203.
30 Ferris RL,Haddad R,Even C,et al.Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma:EAGLE,a randomized,open-label phase III study[J].Ann Oncol,2020,31(7):942-950.
31 Poonia M,Ramalingam K,Goyal S,et al.Nanotechnology in oral cancer:A comprehensive review[J].J Oral Maxillofac Pathol,2017,21(3):407-414.
32 Madhulaxmi M,Iyer K,Periasamy R,et al.Role of cisplatin in oral squamous cell carcinoma-a review[J].J Adv Pharm Educ Res,2017,7:39-42.
33 Lucky SS,Idris NM,Huang K,et al.In vivo biocompatibility,biodistribution and therapeutic efficiency of titania coated upconversion nanoparticles for photodynamic therapy of solid oral cancers[J].Theranostics,2016,6(11):1844-1865.
34 Marcazzan S,Varoni EM,Blanco E,et al.Nanomedicine,an emerging therapeutic strategy for oral cancer therapy[J].Oral Oncol,2018,76:1-7.
35 Li X,Li L,Huang Y,et al.Synergistic therapy of chemotherapeutic drugs and MTH1 inhibitors using a pH-sensitive polymeric delivery system for oral squamous cell carcinoma[J].Biomater Sci,2017,5(10):2068-2078.
36 Wang J,Xie T,Wang B,et al.PD-1 blockade prevents the development and progression of carcinogen-induced oral premalignant lesions[J].Cancer Prev Res(Phila),2017,10(12):684-693.
37 Russo D,Merolla F,Mascolo M,et al.FKBP51 immunohistochemical expression:A new prognostic biomarker for OSCC[J].Int J Mol Sci,2017,18(2):443.
38 Emami N,Mohamadnia A,Mirzaei M,et al.MiR-155,miR-191,and miR-494 as diagnostic biomarkers for oral squamous cell carcinoma and the effects of avastin on these biomarkers[J].J Korean Assoc Oral Maxillofac Surg,2020,46(5):341-347.
39 Chang Y,Tolani B,Nie X,et al.Review of the clinical applications and technological advances of circulating tumor DNA in cancer monitoring[J].Ther Clin Risk Manag,2017,13:1363-1374.
40 Chalmers ZR,Connelly CF,Fabrizio D,et al.Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden[J].Genome Med,2017,9(1):34.
41 Carbone DP,Reck M,Paz-Ares L,et al.First-line nivolumab in stage IV or recurrent non-small-cell lung cancer[J].N Engl J Med,2017,376(25):2415-2426.

[1]	YANG Kaiyan, WEI Yongchang, YANG Qiuyun, TANG Fengzhu. Research progress in immunotherapy of nasopharyngeal carcinoma [J]. Journal of Practical Oncology, 2021, 35(6): 542-546.
[2]	LI Xiang, HU Yang, ZHANG Qingyuan. Research progress of tumor mutational burden as an emerging biomarker for breast cancer immunotherapy [J]. Journal of Practical Oncology, 2021, 35(6): 568-571.
[3]	MENG Di, XU Qianwen, SUN Xiuwei. Expression and clinical significance of heat shock protein 90 in esophageal squamous cell carcinoma [J]. Journal of Practical Oncology, 2021, 35(6): 572-575.
[4]	WANG Zhe, ZHU Shuai, LIU Huan, FU Qiang, HU Tenglong. Expression,correlation and clinical significance of SRPX2 and Rab31 in oral squamous cell carcinoma [J]. Journal of Practical Oncology, 2021, 35(5): 414-419.
[5]	LU Junrong, WANG Huiwen, HE Dongfeng. Significance of high expression of SALL4 in clinicopathological and prognostic judgment of esophageal squamous cell carcinoma [J]. Journal of Practical Oncology, 2021, 35(5): 420-425.
[6]	ZHANG Weiming, SUN Jianping, ZHAO Yan. Co-stimulatory receptors:potential targets for tumor immunotherapy [J]. Journal of Practical Oncology, 2021, 35(5): 441-446.
[7]	WANG Ye, SHANG Naijian. Application progress of radiomics in the diagnosis and treatment of non-small cell lung cancer [J]. Journal of Practical Oncology, 2021, 35(5): 485-488.
[8]	DONG Xiaoping, ZHANG Xue, GUO Dongli, HE Yutong. Research progress on the related factors affecting the prognosis of squamous cell carcinoma of lung [J]. Journal of Practical Oncology, 2021, 35(4): 380-385.
[9]	MA Mingrui, LIAN Jie, LIU Chao, LOU Changjie, ZHANG Yanqiao. Exploration of “immunotherapy moving forward” for digestive system tumors [J]. Journal of Practical Oncology, 2021, 35(3): 258-262.
[10]	XIONG Wei, WANG Dan, WANG Jinhui, ZHANG Ying, CAO Dongyan. Prognostic significance of neutrophil-lymphocyte ratio in vulvar squamous cell carcinoma and vulvar intraepithelial neoplasia [J]. Journal of Practical Oncology, 2021, 35(2): 125-130.
[11]	WANG Mengmeng, LIAN Jie, LI Hengzhen, ZHANG Yanqiao. Research progress in immunotherapy of gastrointestinal pancreatic neuroendocrine tumors [J]. Journal of Practical Oncology, 2021, 35(2): 154-159.
[12]	WANG Mingming, CHEN Xiaopin. Research progress of anti-PD-1/PD-L1 and anti-CTLA-4 immunotherapy in head and neck squamous cell carcinoma [J]. Journal of Practical Oncology, 2021, 35(2): 179-183.
[13]	LIU Xuejing,XU Yanying. Research progress of B7-H6 in malignant tumors [J]. Journal of Practical Oncology, 2021, 35(1): 46-49.
[14]	ZHANG Lu,LU Jingyu,LU Haijun. The relationship between biomarkers of head and neck squamous cell carcinoma and prognosis of immunotherapy [J]. Journal of Practical Oncology, 2021, 35(1): 55-58.
[15]	DANG Yao,HUANG Fuhui,QIN Yixiao,CHE Qin,HAO Xiaolong,WANG Binquan. Research progress of metastatic mechanism and influencing factors of head and neck squamous cell carcinoma [J]. Journal of Practical Oncology, 2021, 35(1): 78-82.

Research progress of immune checkpoint inhibitors in the treatment of oral squamous cell carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments